Biosimilar hormones market seen reaching $18.12 billion by 2030
The biosimilar hormones market is projected to nearly triple from 2025 to 2030, driven by rising diabetes cases, patent expirations on major biologic hormones and stronger demand for lower-cost endocrine treatments. North America held the largest share in 2025 as the market expands across pharmacies, online channels and global healthcare systems.
Why it matters: - Biosimilar hormones are positioned as lower-cost alternatives to branded hormone therapies, which can improve access for patients with diabetes, hormone disorders and other endocrine conditions. - The market’s rapid growth points to broader pressure in healthcare systems to cut treatment costs while keeping therapies available through hospital, retail and online pharmacy channels. - The shift matters for insulin and growth hormone treatment, where demand is rising and biosimilars could ease affordability barriers.
What happened: - The Business Research Company said the biosimilar hormones market will grow from $6.22 billion in 2025 to $7.68 billion in 2026. - The firm projects the market will reach $18.12 billion by 2030. - The forecast implies a 23.5% CAGR from 2025 to 2026 and a 23.9% CAGR through 2030. - North America held the largest share of the biosimilar hormones market in 2025. - The report covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.
The details: - The report cites diabetes, hormonal disorders, high branded hormone prices, an aging population, greater awareness of hormone replacement therapy and wider pharmacy networks as key historical growth drivers. - The forecast period is supported by patent expirations on major biologic hormones, stronger regulatory backing for biosimilars, demand for cost-effective endocrine therapies, online pharmacy growth and more biosimilar R&D investment. - The report identifies wider use of biosimilar hormones as economical substitutes, rising demand for insulin and growth hormone biosimilars, greater physician acceptance, use in chronic and lifestyle diseases, and streamlined approval processes as major trends. - Healthcare spending is one of the main catalysts in the market. - The U.S. healthcare system spent $4.9 trillion in 2023, up 7.5%, according to the Centers for Medicare & Medicaid Services in December 2024. - That works out to about $14,570 per person. - The report says higher healthcare costs can also push adoption of lower-cost biosimilars. - Diabetes is another major demand driver. - The International Diabetes Federation projected in June 2023 that 783 million adults ages 20 to 79 will have diabetes by 2045. - The report describes biosimilar hormones as products that contain hormones chemically identical to those naturally produced by the human body. - These products are designed to treat hormone imbalances or deficiencies and help restore hormonal balance. - The report also highlights new market-report features, including market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics and updated graphics and tables.
Between the lines: - The forecast suggests biosimilar hormones are moving from a niche alternative to a mainstream cost-control tool in endocrine care. - Rising demand for biologic substitutes often follows patent cliffs, and the report points to that pattern as a key reason for future growth. - North America’s lead signals that reimbursement, regulatory readiness and treatment access may be more advanced there than in other regions.
What's next: - The market will likely keep expanding as more biologic hormone patents expire and biosimilars gain broader physician and regulatory acceptance. - Growth should also track rising demand for insulin and growth hormone products as diabetes cases increase worldwide. - The report says online pharmacy channels and biosimilar R&D investment will remain important growth supports. - More information is available in the company’s announcement and a free sample report.
The bottom line: - Biosimilar hormones are on track for fast global growth as healthcare systems seek cheaper alternatives to branded hormone therapies.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Economic News Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.